GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Opus Genetics Inc
Opus Genetics, a privately held gene therapy company, is valued based on its progress in treating rare inherited eye diseases. Its potential share price will depend on the results of clinical trials and its ability to commercialize its breakthrough treatments.
Share prices of companies in the market segment - Pharma eyes
Opus Genetics (ticker: IRD) is a biopharmaceutical company developing gene therapies for the treatment of rare inherited retinal diseases. We classify it in the "Pharmaceuticals (Eye)" sector. The chart below shows the overall performance of this highly specialized segment.
Broad Market Index - GURU.Markets
Opus Genetics is a biotech company specializing in developing gene therapy for rare inherited eye diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Opus shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
IRD - Daily change in the company's share price Opus Genetics Inc
For Opus Genetics Inc., a company focused on gene therapy for eye diseases, daily volatility reflects sensitivity to scientific data. This metric is an important element in formulas that assess the risks and potential of companies in the innovative medical sector.
Daily change in the price of a set of shares in a market segment - Pharma eyes
For Opus Genetics Inc., a company focused on gene therapy for eye diseases, daily volatility reflects sensitivity to scientific data. This metric is an important element in formulas that assess the risks and potential of companies in the innovative medical sector.
Daily change in the price of a broad market stock, index - GURU.Markets
Opus Genetics is a biotech company developing gene therapy for rare eye diseases. Its shares are a bet on a breakthrough in medicine. Their high volatility, driven by research results, contributes to the dynamics of the entire innovative market sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Opus Genetics Inc
Opus Genetics Inc.'s year-over-year performance is a story about developing gene therapy for rare hereditary eye diseases. Its 12-month market cap depends entirely on progress in preclinical and clinical trials. Success could restore vision to patients and validate the potential of its scientific platform.
Annual dynamics of market capitalization of the market segment - Pharma eyes
Opus, a private biotech company, is likely developing gene therapies for rare eye diseases. Its growth depends on success in clinical trials. Its valuation will reflect investor confidence in its scientific platform, potentially outperforming the overall pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Opus Genetics is privately held and not publicly traded. Its market performance cannot be analyzed. As a biotech company focused on treating rare eye diseases, its value is determined solely by clinical trial results and scientific breakthroughs, not by economic factors.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Opus Genetics Inc
Opus Genetics is a biotech company developing gene therapy for rare eye diseases. Being in the early stages, its monthly valuation is based on scientific potential. Progress in preclinical studies and steps toward first-in-human trials are the main drivers.
Monthly dynamics of market capitalization of the market segment - Pharma eyes
Opus Genetics Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies for the treatment of rare inherited retinal diseases. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess how its cutting-edge developments can change the lives of patients suffering from blindness.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
iShares U.S. Regional Banks (IRD) is an exchange-traded fund (ETF) that tracks the U.S. regional banking sector. Its performance is the aggregated performance of dozens of banks. The chart shows how sentiment across the entire sector, sensitive to interest rates and the state of the economy, is reflected in the price of this instrument.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Opus Genetics Inc
Opus Genetics, a company developing gene therapy for eye diseases, is experiencing the extreme volatility typical of cutting-edge biotech. Weekly stock performance hinges on news about clinical trials, where any outcome could radically change the company's future.
Weekly dynamics of market capitalization of the market segment - Pharma eyes
Opus Genetics (IRD) is a company focused on gene therapy for inherited retinal diseases. This is a cutting-edge but risky field. The chart will show how the market reacts to its news compared to the ophthalmology sector, allowing us to assess investor confidence in its unique technologies.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Opus Genetics is a biotech company focused on gene therapy. Its shares exist in a world of their own, where research data is king. The chart shows that IRD's dynamics are almost uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
IRD - Market capitalization of the company Opus Genetics Inc
Opus Genetics' stock price is a financial bet on gene therapy for rare eye diseases. This company's market cap reflects hopes for its ability to restore vision in patients with inherited forms of blindness. Its dynamics are a barometer of progress in clinical development and faith in the revolutionary potential of gene therapy.
IRD - Share of the company's market capitalization Opus Genetics Inc within the market segment - Pharma eyes
Opus Genetics's stake in the ophthalmology sector is in gene therapy for rare inherited retinal diseases. Its market share, though small, is based entirely on the potential of its cutting-edge developments to restore patients' vision.
Market capitalization of the market segment - Pharma eyes
Opus Genetics is a biotech company focused on gene therapy for rare eye diseases. The chart below shows the overall market capitalization of this cutting-edge sector. Its dynamics reflect the hopes that gene therapy can restore vision.
Market capitalization of all companies included in a broad market index - GURU.Markets
Opus Genetics is a biotech company developing gene therapy for rare, inherited eye diseases that lead to blindness. Its market capitalization represents the hope of saving sight. The graph below shows the economic impact of improving quality of life through biotechnology.
Book value capitalization of the company, segment and market as a whole
IRD - Book value capitalization of the company Opus Genetics Inc
Opus Genetics is an early-stage biopharmaceutical company focused on eye diseases. Its book value is primarily cash from investors. The chart below shows how this capital is spent on preclinical research. This is its financial "headroom."
IRD - Share of the company's book capitalization Opus Genetics Inc within the market segment - Pharma eyes
Opus Genetics is a biotech company developing gene therapy for rare eye diseases. Its primary asset is research and development. Its share of tangible assets will be low, reflecting its focus on R&D, with laboratories serving as its primary facilities.
Market segment balance sheet capitalization - Pharma eyes
Opus Genetics is a gene therapy company. Its value is created in laboratories developing drugs to treat rare eye diseases. This is a "light" model. The chart below illustrates the extent to which the biopharmaceutical industry as a whole relies on tangible assets.
Book value of all companies included in the broad market index - GURU.Markets
Opus Genetics' balance sheet represents capital fully focused on developing gene therapy for rare inherited retinal diseases. The book value chart shows the resources devoted to this cutting-edge and complex area of medicine, which offers hope for restoring vision.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Opus Genetics Inc
Opus Genetics, a privately held company, focuses on gene therapy for rare inherited eye diseases. Its value lies solely in its science and intellectual property. If it were publicly traded, its stock price would reflect investors' faith in the breakthrough potential of gene therapy for vision restoration.
Market to book capitalization ratio in a market segment - Pharma eyes
Opus Genetics (likely a biotech company) is focused on gene therapy for eye diseases. The company has virtually no tangible assets; its value is derived from its scientific potential. The chart shows how much investor expectations for this breakthrough technology exceed the value of its current assets.
Market to book capitalization ratio for the market as a whole
Opus Genetics is a biotech company developing gene therapy for rare inherited eye diseases. The chart shows how the market values this cutting-edge medical technology. The company's market capitalization is a pure bet that its technologies will restore vision, which represents a huge but very risky potential.
Debts of the company, segment and market as a whole
IRD - Company debts Opus Genetics Inc
Opus Genetics is a company developing gene therapy for rare inherited retinal diseases. This is a cutting-edge, but extremely capital-intensive, field. This chart shows how the company is raising significant funds to finance its complex preclinical and clinical research.
Market segment debts - Pharma eyes
Opus Genetics is a biotech company focused on gene therapy for rare inherited eye diseases. This is a cutting-edge, but very expensive, field of medicine. The chart shows the financial norms for the biotech sector, where companies raise vast amounts of capital to finance their complex and innovative clinical programs capable of restoring people's sight.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Opus Genetics Inc
Opus Genetics is a company developing gene therapy for rare inherited eye diseases. This is a cutting-edge, but extremely expensive, field of medicine. This chart shows how much Opus Genetics relies on debt to fund its unique research. It's a direct indicator of the financial risks involved in developing a cure.
Market segment debt to market segment book capitalization - Pharma eyes
Developing gene therapies for rare eye diseases, like Opus Genetics', is at the forefront of medicine. This chart shows how the biotech sector is funding its most ambitious projects. It helps us understand how capital-intensive Opus's model is and how it compares to other companies working in gene and cell therapy.
Debt to book value of all companies in the market
Opus Genetics (if it's the correct company for the ticker symbol IRD) is developing gene therapy for rare eye diseases. This is cutting-edge science, requiring massive investment. The chart shows how this pioneering company's debt stacks up against more traditional market sectors.
P/E of the company, segment and market as a whole
P/E - Opus Genetics Inc
This figure for Opus Genetics, a biopharmaceutical company developing gene therapy for rare eye diseases, reflects investor expectations. Its value is determined solely by the potential of its breakthrough technologies, not by current profits. The chart is a barometer of faith in the future of genetic engineering.
P/E of the market segment - Pharma eyes
This indicator represents the average valuation for the biotech sector in which Opus Genetics operates. It reflects the overall level of hope and expectation in the field of gene therapy. The chart serves as a barometer of investor confidence in the future of treating inherited eye diseases.
P/E of the market as a whole
Opus Genetics is a biotech company focused on treating rare genetic retinal diseases. This is a cutting-edge field of gene therapy with enormous potential, but also high risks. This chart shows the market's appetite for innovation. It helps us understand whether the market believes Opus can succeed where many have failed, and how they view this high-risk bet.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Opus Genetics Inc
Opus Genetics is a biotech company developing gene therapy for rare, inherited retinal diseases that lead to blindness. Its future depends entirely on the success of its innovative treatments in the clinic. This chart reflects investors' high, yet speculative, expectations for a breakthrough in the treatment of genetic eye diseases.
%20P%2FE%20Opus%20Genetics%20Inc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Opus-Genetics-Inc&v=1772582726101 "Chart of the company's future (projected) P/E Opus Genetics Inc")
Future (projected) P/E of the market segment - Pharma eyes
Opus Genetics is an early-stage biotech company focused on developing gene therapies to treat rare, inherited retinal diseases that lead to blindness. This chart reflects expectations for the biotech sector, providing context for assessing how the market views this cutting-edge, yet high-risk, field of medicine.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-eyes&v=1772582726275 "Future (projected) P/E graph of the market segment - Pharma eyes")
Future (projected) P/E of the market as a whole
Opus Genetics is a biotech company developing gene therapy for rare, inherited retinal diseases that lead to blindness. This chart of overall expectations demonstrates the market's willingness to fund breakthrough medical technologies. Investor optimism and faith in science are critical to attracting capital for the development of treatments that can restore sight.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772582726301 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Opus Genetics Inc
Opus Genetics is an early-stage biotech company focused on developing gene therapies for rare inherited retinal diseases. This chart shows the financial health of a startup working at the cutting edge of science. Profit is a long-term goal, and operating expenses reflect investments in preclinical research.
Profit of companies in the market segment - Pharma eyes
IGC Pharma, Inc. is conducting clinical trials of cannabinoid-based drugs for the treatment of Alzheimer's disease. This represents the intersection of two high-risk fields. This graph reflects the state of the niche, where the potential reward for success is enormous, but scientific, clinical, and regulatory risks make the path to profitability extremely difficult and uncertain.
Overall market profit
Opus Genetics is a biotechnology company in the early stages of developing gene therapy for rare inherited eye diseases. Its goal is not just to treat, but to restore vision. The company's success depends on scientific breakthroughs and represents a bet on the future of medicine, addressing the root cause of disease.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Opus Genetics Inc
Opus Genetics is an early-stage biotech company focused on developing gene therapies for rare inherited retinal diseases. Revenue projections are extremely long-term and speculative. The chart would reflect analysts' faith in the company's scientific platform and its potential to save patients' sight.
%20profit%20of%20the%20company%20Opus%20Genetics%20Inc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Opus-Genetics-Inc&v=1772582726394 "Graph of future (projected) profit of the company Opus Genetics Inc")
Future (predicted) profit of companies in the market segment - Pharma eyes
Opus Genetics is a biotech company focused on developing gene therapies to treat rare, inherited retinal diseases that lead to blindness. This is a cutting-edge and highly complex segment of medicine. This chart shows profitability projections for the biotech sector. It reflects the enormous promise and risks associated with gene therapy and the treatment of rare diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-eyes&v=1772582726466 "Graph of future (predicted) profits of companies in a market segment - Pharma eyes")
Future (predicted) profit of the market as a whole
Opus Genetics is developing gene therapy for rare inherited eye diseases. This is cutting-edge medicine, requiring massive investment. The overall corporate profit outlook, shown in this chart, influences investor risk appetite and the flow of capital into the biotech sector, which is crucial for funding such breakthrough research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772582726548 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Opus Genetics Inc
Opus Genetics is a biotech company developing gene therapy for rare, inherited retinal diseases that lead to blindness. Being in the early stages, it has no revenue. The chart reflects the speculative valuation of its cutting-edge technology and the hope that it will be able to restore vision to patients with genetic defects.
P/S market segment - Pharma eyes
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for the treatment of rare, inherited retinal diseases that cause blindness. This chart shows the average valuation in the sector, allowing one to assess how the market perceives the revenue potential of Opus Genetics' cutting-edge technologies.
P/S of the market as a whole
Opus Genetics is a biotech company focused on developing gene therapies to treat rare, inherited retinal diseases that lead to blindness. This chart, showing average valuations, clearly demonstrates the gap between the valuations of companies with current sales and the value of scientific platforms with enormous potential.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Opus Genetics Inc
Opus Genetics is a biotech company focused on developing gene therapies for the treatment of rare inherited retinal diseases. This chart reflects investors' confidence in the future success of its programs. The valuation is based on potential revenue from drugs that can restore vision to patients with previously untreated options.
%20P%2FS%20Opus%20Genetics%20Inc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Opus-Genetics-Inc&v=1772582726755 "The graph of the company's future (projected) P/S Opus Genetics Inc")
Future (projected) P/S of the market segment - Pharma eyes
Opus Genetics is developing gene therapy for rare, inherited retinal diseases that lead to blindness. Its goal is to restore vision in patients with genetic defects. The chart below shows how investors estimate Opus's future sales, reflecting the enormous potential of its breakthrough treatments in ophthalmology.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-eyes&v=1772582726815 "Future (projected) P/S market segment graph - Pharma eyes")
Future (projected) P/S of the market as a whole
Future revenue expectations in biotech hinge on breakthroughs in gene therapy. Opus Genetics, like many companies in this field, focuses on treating inherited diseases, in this case, retinal diseases. Their work raises hope that genetic defects can be corrected, opening a new era in medicine and offering enormous growth potential.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772582726907 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Opus Genetics Inc
Opus Genetics is an early-stage biotech company focused on gene therapy for rare inherited retinal diseases. The company has no commercial products yet, and its financial curve reflects funding milestones for its cutting-edge vision-restoring research, not revenue.
Sales of companies in the market segment - Pharma eyes
Opus Genetics is a biopharmaceutical company developing gene therapy for the treatment of rare, inherited retinal diseases that lead to blindness. This chart shows the company's total revenue in the ophthalmology pharmaceutical sector. It illustrates the hopes of gene therapy, which can correct a genetic defect and restore vision in a single step.
Overall market sales
Opus Genetics is a biotech company developing gene therapy for rare, inherited retinal diseases that lead to blindness. Being an early-stage company, its value lies in the potential of its developments. This general economic climate affects the availability of venture capital for funding cutting-edge and expensive medical technologies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Opus Genetics Inc
Opus Genetics is an early-stage biopharmaceutical company focused on developing gene therapies for the treatment of rare inherited retinal diseases. Its future depends entirely on success in R&D. Revenue guidance is highly speculative and reflects only the most distant expectations of analysts regarding future commercialization.
%20sales%20of%20the%20company%20Opus%20Genetics%20Inc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Opus-Genetics-Inc&v=1772582727109 "Schedule of future (projected) sales of the company Opus Genetics Inc")
Future (projected) sales of companies in the market segment - Pharma eyes
Opus Genetics is a biotechnology company focused on gene therapy for rare, inherited retinal diseases that lead to blindness. The company's success depends on clinical data. This chart displays projected sales for the entire ophthalmic pharmaceutical segment, highlighting overall growth expectations for the ocular gene therapy market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-eyes&v=1772582727185 "Schedule of future (projected) sales of companies in the market segment - Pharma eyes")
Future (projected) sales of the market as a whole
Opus Genetics (formerly Iridex) specializes in gene therapy for rare inherited retinal diseases. The company is in its early stages, and its future depends on the success of its scientific platform. This overall economic activity schedule impacts the availability of venture capital, which is critical for funding breakthrough, yet very long-term, research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772582727245 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Opus Genetics Inc
Opus Genetics is an early-stage biotech company focused on gene therapy for rare inherited eye diseases. This metric reflects the startup's financial reality. It demonstrates the required investment in preclinical and early clinical trials, which forms the foundation for future value creation.
Market segment marginality - Pharma eyes
Opus Genetics is a biotechnology company developing gene therapy for rare inherited eye diseases. Profitability is a long-term goal. This metric reflects its operational structure and the intensity of its investment in cutting-edge science compared to other companies working in the field of ophthalmic gene therapy.
Market marginality as a whole
Opus Genetics is an early-stage biotech company focused on developing gene therapies for rare, inherited retinal diseases. Their goal is to restore vision to patients. Their success depends on scientific breakthroughs and funding. This profitability curve does not affect their operations, which are at the forefront of medical science.
Employees in the company, segment and market as a whole
Number of employees in the company Opus Genetics Inc
Opus Genetics is an early-stage biotech company focused on developing gene therapies for rare inherited eye diseases. Its team is very small. This chart shows the minimum research team size typical for a startup focused on basic research and preclinical development.
Share of the company's employees Opus Genetics Inc within the market segment - Pharma eyes
Opus Genetics, a subsidiary of the Retinal Degeneration Fund, is developing gene therapy for rare inherited retinal diseases. This chart shows the concentration of unique scientists in the field of ophthalmic gene therapy. Their team is at the forefront of science, striving to restore vision.
Number of employees in the market segment - Pharma eyes
Opus Genetics Inc. is an early-stage biotech company developing gene therapy for rare inherited retinal diseases. This chart shows overall employment in the ophthalmology sector. It illustrates the cutting edge of science, where Opus Genetics strives to create treatments that can restore vision in patients.
Number of employees in the market as a whole
Opus Genetics is a company developing gene therapy for rare, inherited retinal diseases that lead to blindness. It's at the forefront of medical science. This chart illustrates the labor market, where unique companies working on breakthrough technologies are emerging. Opus is creating a demand for geneticists, ophthalmologists, and gene vector production specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Opus Genetics Inc (IRD)
Opus Genetics is a biopharmaceutical company developing gene therapy for rare eye diseases. This chart is a prime example of biotech. The astronomically high market capitalization per employee suggests that the market is valuing the potential of a breakthrough technology to save patients' vision, not the operational activities of a small research team.
%20of%20the%20company%20Opus%20Genetics%20Inc%20(IRD)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Opus-Genetics-Inc-IRD&v=1772582727614 "Chart of market capitalization per employee (in thousands of dollars) of the company Opus Genetics Inc (IRD)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma eyes
Opus Genetics, as its name suggests, is a biotech company focused on gene therapy for eye diseases. This is one of the most advanced areas of medicine. This metric reflects the enormous premium the market places on their potentially revolutionary technologies. The high metric reflects investors' belief that a small team of scientists can transform patients' lives.
%20by%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-eyes&v=1772582727685 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma eyes")
Market capitalization per employee (in thousands of dollars) for the overall market
Opus Genetics Inc. is a biopharmaceutical company developing gene therapy for the treatment of rare inherited eye diseases. Its valuation is based on the potential of its breakthrough technology. Its high market capitalization reflects the enormous hope that its developments will restore vision and cure previously incurable diseases.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772582727691 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Opus Genetics Inc (IRD)
Opus Genetics (IRD) is a privately held early-stage biotech company focused on developing gene therapies for rare inherited retinal diseases. This chart reflects their R&D status: it shows the net loss (investment in research) per scientist working on this cutting-edge therapy.
%20Chart%20Opus%20Genetics%20Inc%20(IRD)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Opus-Genetics-Inc-IRD&v=1772582727710 "Company Profit Per Employee (in thousands of dollars) Chart Opus Genetics Inc (IRD)")
Profit per employee (in thousands of dollars) in the market segment - Pharma eyes
Opus Genetics is a very early-stage company developing gene therapy for rare eye diseases. At this stage of R&D, this metric isn't applicable. The graph represents a benchmark for mature pharmaceutical companies. Opus's goal is to create a breakthrough treatment that will deliver colossal returns, far exceeding any standard.
%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-eyes&v=1772582727750 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma eyes")
Profit per employee (in thousands of dollars) for the market as a whole
Opus Genetics (IRD) is an early-stage biotech company focused on gene therapy for rare inherited retinal diseases. This is cutting-edge and expensive science. This metric would be deeply negative for them, as their small team of scientists is spending venture capital on research.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772582727769 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Opus Genetics Inc (IRD)
For Opus Genetics, a company developing gene therapy for rare inherited eye diseases, this graph reflects the earliest stages of development. Revenue per employee, if any, comes from grants, and commercial success is still a long way off.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Opus-Genetics-Inc-IRD&v=1772582727778 "Sales chart per company employee Opus Genetics Inc (IRD)")
Sales per employee in the market segment - Pharma eyes
Opus Genetics is an early-stage biotech company specializing in gene therapy for rare inherited retinal diseases. This R&D metric reflects the average revenue per employee for the segment. It demonstrates how productive their research team is in this cutting-edge field compared to other gene therapy companies.
Sales per employee for the market as a whole
Opus Genetics (IRD) is an early-stage biopharmaceutical company focused on gene therapy for rare inherited retinal diseases. Currently, its staff consists entirely of researchers. This metric is critical for IRD: it's at zero. Its future growth will signal the success of their R&D platform.
Short shares by company, segment and market as a whole
Shares shorted by company Opus Genetics Inc (IRD)
Opus Genetics is a very early-stage biotech company focused on gene therapy for rare eye diseases. This is a highly speculative field. This graph likely reflects investors' high skepticism about the company's ability to bring its preclinical developments to successful clinical trials, which requires a significant amount of capital.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Opus-Genetics-Inc-IRD&v=1772582727942 "Short Shares Chart for the Company Opus Genetics Inc (IRD)")
Shares shorted by market segment - Pharma eyes
Opus Genetics (IRD) is a clinical-stage gene therapy company focused on treating rare inherited retinal diseases. This chart shows the cumulative short interest in the speculative gene therapy sector. It reflects the immense skepticism of investors regarding the technical, manufacturing, and regulatory barriers in this highly complex field of medicine.
Shares shorted by the overall market
Opus Genetics (IRD) is a clinical-stage biotech company working on eye diseases. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, unprofitable biotechs like IRD.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Opus Genetics Inc (IRD)
This oscillator is a clear barometer of hope in gene therapy for Opus Genetics. The company treats rare inherited retinal diseases. These are binary bets. Any positive preclinical data or the start of human trials triggers a surge of euphoria and "overheating" (above 70). The slightest delay or concerns about the safety of gene delivery lead to panic (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Opus-Genetics-Inc-IRD&v=1772582728018 "RSI 14 indicator chart for the company's stock Opus Genetics Inc (IRD)")
RSI 14 Market Segment - Pharma eyes
Opus Genetics (IRD) is a "biotech" vision "savior." They focus *only* on *gene therapy* (AAV) for the treatment of *rare inherited* retinal diseases. The "Pharma eyes" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of the *entire* segment. It's vital to understand: is IRD's growth due to their R&D, or is *the entire* biotech "overheated"?
RSI 14 for the overall market
For Opus Genetics, a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IRD (Opus Genetics Inc)
Opus Genetics (IRD) is an early-stage biopharmaceutical company developing gene therapies for rare, inherited retinal diseases that lead to blindness. This chart shows the speculative average price target from analysts based on their belief in this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IRD-Opus-Genetics-Inc&v=1772582728396 "A chart showing analyst consensus forecasts for the expected stock price. IRD (Opus Genetics Inc)")
The difference between the consensus estimate and the actual stock price IRD (Opus Genetics Inc)
IRD - Opus Genetics is a biotech company focused on developing gene therapies to treat rare, inherited retinal diseases that lead to blindness. This chart measures the gap between the current share price and the consensus target price. It highlights the enormous, yet risky, potential analysts see in this technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IRD-Opus-Genetics-Inc&v=1772582728469 "A chart showing the difference between the consensus forecast and the actual stock price. IRD (Opus Genetics Inc)")
Analyst consensus forecast for stock prices by market segment - Pharma eyes
Opus Genetics (IRD) is a biotech company developing gene therapy for rare, inherited retinal diseases that lead to blindness. This chart shows general expectations for the ophthalmology sector, reflecting whether experts believe in the commercial success of this complex and expensive R&D technology.
Analysts' consensus forecast for the overall market share price
Opus Genetics (IRD) is an early-stage biotech company developing gene therapies to treat rare, inherited eye diseases that cause blindness. This chart shows the overall risk appetite. For Opus, operating in a complex field, overall market optimism is critical to raising the capital needed to fund long-term trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Opus Genetics Inc
IRD (Opus Genetics) is a clinical-stage biotech focused on the most complex challenge—gene therapy for rare inherited eye diseases (blindness). This graph represents pure R&D betting. Its valuation is a lottery ticket: the market's faith in their (very early) scientific platform and their ability to restore vision.
AKIMA Market Segment Index - Pharma eyes
Opus Genetics (IRD) is a biotech company specializing in gene therapy for rare inherited retinal diseases. This chart shows the average pharma sector index, helping investors assess how Opus's innovative and highly specialized approach compares to the industry average.
The AKIM Index for the overall market
Opus Genetics is a gene therapy company focused on treating inherited retinal diseases that lead to blindness. This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop critical to funding this niche but important research.
